Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12282165 | 0.89 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL31691915 | 0.83 | IDO1 (0.39) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28435982 | 0.79 | OPRM1 (0.45) | SLC6A4SLC6A2SLC6A3CFTRGOPC | |
| SCHEMBL19144912 | 0.77 | IDO1 (0.64) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2482817 | 0.74 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6CFTR | |
| SCHEMBL6631615 | 0.74 | CFTR (0.52) | SLC6A4SLC6A2SLC6A3CFTRGOPC | |
| SCHEMBL792191 | 0.74 | CFTR (0.52) | SLC6A4SLC6A2SLC6A3CFTRGOPC | |
| Hydrochloric Acid SCHEMBL4795565 | 0.73 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3CYP2D6CFTR | |
| SCHEMBL8795521 | 0.73 | SMN1; SMN2 (0.53) | SLC6A4SLC6A2SLC6A3CYP2D6CFTR | |
| SCHEMBL30896272 | 0.73 | SMN1; SMN2 (0.53) | SLC6A4SLC6A2SLC6A3CYP2D6CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10548891-B2 | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20150352106-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-10 | — | — | US | disclosed |
| US-20150352106-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-10 | — | — | US | disclosed |
| US-9150569-B2 | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150569-B2 | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2570411-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING KYNURENINE PRODUCTION INHIBITORY ACTIVITY | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065905-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SLC6A4 122/4885SLC6A2 294/4885SLC6A3 300/4885 |
| US-20150352106-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SLC6A4 122/4885SLC6A2 294/4885SLC6A3 300/4885 |
| US-10548891-B2 | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | KYNU, KMO, IDO1 | SLC6A4 122/4885SLC6A2 294/4885SLC6A3 300/4885 |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SLC6A4 122/4885SLC6A2 294/4885SLC6A3 300/4885 |
| US-20130065905-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | SLC6A4 122/4885SLC6A2 288/4885SLC6A3 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.